2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Metabolic Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1376 Selection for JAK transactivation rewires cytokine signaling and creates a reversible therapeutic vulnerability to interferon-α

Madison Fitzsimmons, Lucas Wadley, PhD, BS2, Angela Fleischman, MD, PhD3
1 University of California, Irvine, Irvine, California, United States
2 University of California, Irvine, Irvine, California, United States
3 University of California, Irvine, Irvine, California, United States

Background: Adaptive signaling mechanisms acquired by malignant cells often enable them to survive under selective pressure. However, these evolutionary adaptations may simultaneously create collateral therapeutic vulnerabilities. While investigating cytokine receptor signaling, we unexpectedly found that Ba/F3 cells expressing IL-10R and JAK2V617F acquired cytokine-independent growth. Because JAK2 is not a canonical component of the IL-10 receptor signaling complex, we investigated the underlying mechanism and found that transformation was mediated through JAK2V617F transactivation of JAK1. Given that both IL-10 receptor and interferon-α receptor (IFNAR) signaling utilize JAK1/TYK2-dependent STAT activation, we hypothesized that adaptive JAK transactivation intrinsically amplifies IFNα signaling, inducing enhanced IFNα sensitivity in biological environments in which transactivation is selected for.

Methods: Ba/F3 cells expressing mIL-10R/JAK2V617F, mMPL/JAK2V617F, hMPL/CALRdel52, or hMPLW515L were studied. IFNα sensitivity was assessed by proliferation and viability assays, and IFNα signaling was evaluated by phospho-STAT1 immunoblotting following IFNα stimulation. To determine whether enhanced IFNα responsiveness applied more broadly to clinically relevant adaptive signaling states, ruxolitinib-resistant derivatives were generated by gradual dose escalation until at least a two-fold increase in ruxolitinib IC50 was achieved. Resistant cells were subsequently evaluated before and after ruxolitinib withdrawal.

Results: Consistent with our hypothesis, IL-10R/JAK2V617F cytokine-independent cells demonstrated significantly greater sensitivity to IFNα than non-transformed IL-10R/JAK2V617F cells, indicating that selection for JAK transactivation simultaneously enabled cytokine-independent growth while creating enhanced IFNα responsiveness. To determine whether this represented a general consequence of adaptive JAK transactivation rather than a unique feature of IL-10R signaling, we generated ruxolitinib-resistant derivatives of MPL/JAK2V617F, MPLW515L, MPL/CALRdel52, and IL-10R/JAK2V617F cells. Across all models, resistant cells demonstrated significantly greater sensitivity to IFNα than naïve cells. Resistant cell lines with the driver mutations of interest showed a 50-80% drop in IFNα IC50, while resistant IL-10R/JAK2V617F cells had values ~25% lower than their naïve counterparts. Consistent with transactivation being the underlying mechanism, the difference between naïve and resistant IL-10R/JAK2V617F cells was comparatively modest because these cells already rely on adaptive JAK transactivation before the acquisition of JAK inhibitor resistance. Enhanced biological sensitivity was accompanied by augmented IFNα signaling, with inhibitor-resistant cells having pSTAT1/STAT1 ratios 2-10x higher than naïve cells of the same line when stimulated with the same concentration of IFNα. Furthermore, transactivating cells exhibited baseline pSTAT1/STAT1 ratios of 0.11-0.23 in the absence of IFNα stimulation compared to barely detectable (0.02-0.03) levels expressed in non-transactivating cell lines. Following withdrawal of ruxolitinib, resistant cells progressively regained baseline sensitivity to both ruxolitinib and IFNα within 7-14 days, linking the biochemical loss of JAK transactivation and loss of IFNα sensitivity.

Conclusions: These studies identify adaptive JAK transactivation as a previously unrecognized determinant of IFNα responsiveness. Rather than simply mediating persistence during JAK inhibitor therapy, adaptive JAK transactivation rewires cytokine signaling in resistant cells. A significant consequence of this altered signaling is the creation of a reversible state of enhanced IFNα sensitivity. More broadly, these findings demonstrate that adaptive signaling states selected to enhance malignant cell fitness can simultaneously create collateral therapeutic vulnerabilities. This work provides a mechanistic rationale for exploiting adaptive JAK transactivation through rational sequencing or intermittent scheduling of JAK inhibitors and IFNα to selectively eliminate persistent MPN clones.

Madison Fitzsimmons: No relevant conflicts of interest to declare.